Faculty

Lindsey A. George, M.D.

faculty photo
Assistant Professor of Pediatrics (Hematology)
Department: Pediatrics
Graduate Group Affiliations

Contact information
Children's Hospital of Philadelphia
3501 Civic Center Blvd
Philadelphia, PA 19104
Education:
BS (Biology)
Cornell University, 2004.
MD
State University at Buffalo School of Medicine and Biological Sciences, 2008.
MSTR (Translational Research)
University of Pennsylvania School of Medicine, 2021.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Coagulation disorders and gene therapy for monogenic disorders

Description of Research Expertise

Dr. Lindsey George is an Assistant Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania and Director of Clinical In Vivo Gene Therapy and Attending Hematologist at the Children’s Hospital of Philadelphia. Her laboratory studies the molecular basis of coagulation with a focus on mechanisms that regulate factor VIII/VIIIa cofactor function to improve understanding of associated disease states of deficiency (hemophilia A) or excess function (thrombosis). Ongoing studies in her group aim to exploit their biochemical insights of FVIII function to develop novel gene-based therapies for hemophilia A. Dr. George has led early-phase, adeno-associated virus (AAV) mediated gene transfer trials for hemophilia A and B. Her Clinical In Vivo Gene Therapy group conducts and supports translational and clinical research in in vivo gene addition and editing as well as aims to implement licensed AAV vectors safely and efficiently across the institution. Dr. George is a member of the Board of Directors of the American Society of Gene and Cell Therapy and participates in multiple national and international professional societies for hemostasis and gene therapy research.

Selected Publications

Keselman DJ, Small JC, Seneviratne T, McCague S, Kaschak TL, Yum SW, O'Brien A, Brandsema JF, Diamond T, Loomes KM, Lin KY, Wittlieb-Weber CA, Mayer OH, Daniel SG, Waldman AT, Samelson-Jones BJ, Matesanz SE, George LA: Real-World Outcomes of Delandistrogene Moxeparvovec Gene Therapy: Motor Outcomes and Emerging Safety Concerns. Mol Ther Page: doi: 10.1016, Oct 2025 Notes: epub ahead of print.

Morris JJ, Parsons NA, Wilhelm AR, Davidson RJ, Olenick LK, Watson CT, Vanden Heuvel A, George LA: Factor IXa and Factor X Influence Factor VIIIa Stability and Inactivation Mechanisms In Vitro and In Vivo. Blood Page: doi: 10.1182, Sep 2025 Notes: epub ahead of print.

Byrne BJ, Flanigan KM, Matesanz SE, Finkel RS, Waldrop MA, D'Ambrosio ES, Johnson NE, Smith BK, Bönnemann C, Carrig S, Rossano JW, Greenberg B, Lalaguna L, Lara-Pezzi E, Subramony S, Corti M, Mercado-Rodriguez C, Leon-Astudillo C, Ahrens-Nicklas R, Bharucha-Goebel D, Gao G, Gessler DJ, Hwu WL, Chien YH, Lee NC, Boye SL, Boye SE, George LA: Current clinical applications of AAV-mediated gene therapy. Mol Ther 33(6): 2479-2516, Jun 2025.

Milone MC, Mansilla-Soto J, Pardi N, George LA, Byrne BJ, Herzog RW. : Clinical advances in gene, cell, and RNA therapies. Mol Ther 33(6): 2311, Jun 2025.

Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, Hacker JL, Hsu A, Silverstein RA, Hille LT, Ogul AN, Robinson-Garvin NA, Small JC, McCague S, Burke SM, Wright CM, Bick S, Indurthi V, Sharma S, Jepperson M, Vakulskas CA, Collingwood M, Keogh K, Jacobi A, Sturgeon M, Brommel C, Schmaljohn E, Kurgan G, Osborne T, Zhang H, Kinney K, Rettig G, Barbosa CJ, Semple SC, Tam YK, Lutz C, George LA, Kleinstiver BP, Liu DR, Ng K, Kassim SH, Giannikopoulos P, Alameh MG, Urnov FD, Ahrens-Nicklas RC: Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease. N Engl J Med 392(22): 2235-2243, Jun 2025.

Rasko JEH*, Samelson-Jones BJ*, George LA, Giermasz A, Ducore JM, Teitel JM, McGuinn CE, High KA, de Jong YP, Chhabra A, O’Brien A, Smith LM, Winburn I, Rupon J: Fidanacogene Elaparvovec for Hemophilia B: A Multi-Year Follow-Up Study. N Engl J Med 392(15): 1508-1517, Apr 2025.

Doshi BS, Markmann CA, Novak N, Rojas SJ, Davidson R, Chau JQ, Wang W, Carrig S, Rus CM, Samelson-Jones BJ, Small JC, Bhoj VG, George LA: Use of CD19-targeted Immune Modulation to Eradicate AAV Neutralizing Antibodies. Mol Ther 8(1): 177-7, Mar 2025 Notes: Published with an accompanying editorial.

Samelson-Jones BJ, Doshi BS, George LA: Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies. Blood 144(21): 2185-2197, Nov 2024.

Samelson-Jones BJ, Small JC, George LA. : Roctavian Gene Therapy for Hemophilia A. Blood Adv 8(19): 5179-5189, Oct 2024.

Lee K, Chau JQ, Suber YB, Sternberg AR, Pishko A, George LA, Bhoj V, Doshi BS, Samelson-Jones BJ: Enhanced Procoagulant Activity of Select Hemophilia B Causing Factor IX Variants with Emicizumab. Blood 144(11): 1230-1235, Sep 2024.

back to top
Last updated: 10/21/2025
The Trustees of the University of Pennsylvania